Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center GlobeNewswire August 05, 2025 IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” […]

OTSAW Awarded National Group Purchasing Agreement and Technology Breakthrough Designation for its Autonomous Mobile Service Robots with Premier, Inc. Premier offers technology breakthrough designations to innovations that offer a major advantage in terms of patient safety, clinical outcomes and operational efficiencies GlobeNewswire August 05, 2025 SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) — Otsaw Limited (“OTSAW,”

ZenaTech Closes a Seventh Drone as a Service (DaaS) Acquisition in North Carolina Expanding its Southeast Region and Government Opportunities GlobeNewswire August 05, 2025 VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a business technology solution provider specializing in AI-powered drones, Drone as a Service

Nuwellis Announces the First Successful Outpatient Application of the Aquadex Smartflow(R) System Under New CMS Code Supported by the recent CMS decision to increase the reimbursement rate, which facilitates broader use of the therapy in outpatient settings GlobeNewswire August 05, 2025 MINNEAPOLIS, Aug. 05, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology

Core Molding Technologies Announces 2026 Leadership Transition CEO Dave Duvall to Retire May 2026, COO Eric Palomaki to Succeed Duvall GlobeNewswire August 05, 2025 COLUMBUS, Ohio, Aug. 05, 2025 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products,

Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study GlobeNewswire August 05, 2025 TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a contract with

Integracare Inc., a leader in private home healthcare in Toronto and Mississauga is expanding to Ottawa and the surrounding area. Under the leadership of home care veteran, Kristine McGinn, Integracare aims to provide Ottawa Seniors with the highest quality home care in the area. https://mma.prnewswire.com/media/2741245/Integracare_Inc_Integracare_Inc__Expands_to_Ottawa_and_Hires_Kri.jpg “I am thrilled to announce that I am joining Integracare

Fayetteville, Ark., Aug. 05, 2025 (GLOBE NEWSWIRE) — Acres.com, the leading land data and mapping platform, today announced it has reached a key milestone with its 12th Farm Credit organization adopting the platform through the FCCS Passkey Program. The milestone marks continued growth as Acres enters its second year in the program, driven by lenders'

(NASDAQ:VANI), LIBERATE-1, the first-in-human application of Vivani's NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study's primary objectives New NPM-139 (semaglutide implant) preclinical feasibility data showed approximately 20% weight loss maintained longer than 6 months with a single implant, continuing to support the

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115 GlobeNewswire August 05, 2025 LIBERATE-1, the first-in-human application of Vivani's NanoPortalTM implant technology, showed a positive safety and tolerability profile,